Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches.
Summary
This mechanistic study investigates human islets to define transcriptome signatures associated with functional recovery of β cells in the context of type 2 diabetes remission after diet, surgery, or pharmacotherapy. The signatures are positioned to unveil therapeutic approaches that promote β-cell recovery.
Key Findings
- Defines transcriptome signatures linked to functional recovery of human β cells in T2D remission contexts.
- Anchors therapeutic hypothesis generation for boosting β-cell function based on human islet molecular profiles.
- Positions diet-, surgery-, and drug-induced remission as contexts to study β-cell plasticity and repair programs.
Clinical Implications
Although preclinical, the identified β-cell recovery signatures could prioritize therapeutic targets and biomarkers for interventions aiming at T2D remission and sustained β-cell function.
Why It Matters
It provides a human tissue-based molecular map of β-cell recovery, a critical step toward disease-modifying therapies in T2D. The transcriptomic framework can guide target discovery and translational strategies.
Limitations
- Abstract details on sample size and validation cohorts are not provided in the excerpt
- Translational efficacy requires functional validation and clinical studies
Future Directions
Functionally test candidate pathways and targets emerging from signatures in multi-system models and early-phase clinical studies; develop biomarkers to track β-cell recovery in remission.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical mechanistic analysis using human tissues; hypothesis-generating
- Study Design
- OTHER